Andy Weymann

Venture Partner, Frontiers in Health & Bio Investments
Andy brings over 20 years of executive and board-level experience across the MedTech and Biotech sectors. With an extensive operational background in regenerative medicine, cell therapy, and medical devices, he has navigated the growth journey from university spin-offs to global platforms. Andy has participated in over 30 strategic transactions, most recently advising 30 Technology on the $230 million acquisition of its wound vertical by Convatec. Currently, he leverages his operator-led perspective to advise high-growth companies like EarlySight and Piomic Medical on clinical strategy and investor positioning.

Linked in Link

I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Our Investment Topics

Energy & Resources

Resilience inEnergy & Resources

Our future success in fields like computing and pharma relies on a resilient energy infrastructure. We focus on disruptive innovations that leverage collaboration with leading enterprises to scale the next industrial base.

Explore
Future of Computing

Future ofComputing

Our progress in various fields, from everyday use to pharma and research, is increasingly driven by computing capabilities, driving a huge demand for compute.

Explore
Bio & Health Verve Keyvisual

Frontiers inHealth & Bio

Advances in healthcare and life sciences are increasingly driven by the convergence of biology, engineering, and data. This convergence is unlocking more precise, efficient, and accessible solutions for patients.

Explore

Privacy Preference Center